All In Biotech

Drug Trial Radar · NCT01499290

Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections

A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults

Last checked: Nov 20, 2026Latest source record: Sep 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 493 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

493

Actual

Start

Mar 2012

Primary completion

Apr 2014

Study completion Apr 2014

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Forest Laboratories
First posted
Dec 26, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.

Conditions

  • Complicated Intra-Abdominal Infection

Interventions

  • CAZ-AVIDrug

    Ceftazidime 2000 mg and 500 mg of avibactam

  • MetronidazoleDrug

    500 mg of Metronidazole

  • MeropenemDrug

    1 gram of Meropenem

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Response at the Test of Cure (TOC) Visit in the Microbiologically Modified Intent-To-Treat (mMITT) Analysis Set (Primary Outcome for FDA).Time frame: TOC: 28 to 35 days after start of study drug
  2. Clinical Response at the TOC Visit in the Modified Intent-To-Treat Analysis Set (Co-primary Outcome for Rest of World [ROW]).Time frame: TOC: 28 to 35 days after start of study drug
  3. Clinical Response at the TOC Visit in the Clinically Evaulable (CE) Analysis Set (Co-primary Outcome for Rest of World [ROW]).Time frame: TOC: 28 to 35 days after start of study drug

Locations

56 sites in 20 countries. Site status is shown where the registry gives one.

  • Research Site

    Chula Vista, California

  • Research Site

    San Diego, California

  • Research Site

    St Louis, Missouri

  • Research Site

    Somers Point, New Jersey

  • Research Site

    Córdoba, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Rousse, Bulgaria

  • Research Site

    Varna, Bulgaria

  • Research Site

    Zagreb, Croatia

  • Research Site

    Děčín, Czechia

  • Research Site

    Hradec Králové, Czechia

  • Research Site

    Jihlava, Czechia

  • Research Site

    Olomouc, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Teplice, Czechia

  • Research Site

    Budapest, Hungary

  • Research Site

    Székesfehérvár, Hungary

  • Research Site

    Bangalore, India

  • Research Site

    Pune, India

  • Research Site

    Trivandrum, India

  • Research Site

    Vadodara, India

  • Research Site

    Hadera, Israel

  • Research Site

    Haifa, Israel

  • Research Site

    Riga, Latvia

  • Research Site

    Alor Star, Malaysia

  • Research Site

    Durango, Mexico

  • Research Site

    Guadalajara, Jalisco, Mexico

  • Research Site

    Mexico City, Mexico

  • Research Site

    's-Hertogenbosch, Netherlands

  • Research Site

    Enschede, Netherlands

  • Research Site

    Arequipa, Peru

  • Research Site

    Cercardo de Lima, Peru

  • Research Site

    Lima, Peru

  • Research Site

    Trujillo, Peru

  • Research Site

    Cluj-Napoca, Romania

  • Research Site

    Iași, Romania

  • Research Site

    Kemerovo, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Saratov, Russia

  • Research Site

    Vsevolozhsk, Russia

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.